ReviewHeart failure reviews2024
Targeting estrogen receptor signaling for treating heart failure.
Review in Heart failure reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Sex differences in cardiovascular‑kidney‑metabolic syndrome: From pathogenesis to treatment response (Review).International journal of molecular medicine · 2026Review
- Desidustat's cardioprotective mechanisms in heart failure: a network pharmacology, molecular docking and dynamics approach.Scientific reports · 2026Article
- The association between serum follicle-stimulating hormone and luteinizing hormone levels and congestive heart failure in postmenopausal women: a cross-sectional study.Scientific reports · 2026Article
- Positive effects of student-led health promotion activities at mass gathering events on health modification behaviors.Journal of public health (Oxford, England) · 2026Article
- Hidden Cardiovascular Risk: Early Menopause Triggering Acute Coronary Syndrome (ACS) in Young Patients.Cureus · 2026Article
- Cardiovascular risk in primary aldosteronism: inflammatory drivers, residual risk, and emerging combination strategies.Frontiers in endocrinology · 2026Review
- Unveiling Heart Failure: Gender-Specific Insights and Innovations in Women's Cardiac Health.Current pharmaceutical design · 2026Review
- Ceramide as a Biomarker for HFpEF in Women: Menopause, Aging, and Pregnancy.International journal of molecular sciences · 2025Review
- Cardiotoxic effects of Bisphenol-A in male Wistar rats are attenuated byJournal of traditional and complementary medicine · 2025Article
- Vascular function in women with heart failure with preserved ejection fraction: a mismatch beyond diastole.Journal of applied physiology (Bethesda, Md. : 1985) · 2025Review
- Article
- Particulate matter and co-occurring genetic risk induce oxidative stress and cardiac and brain Alzheimer's pathology.Communications biology · 2025Article
- Article
- Sex Chromosomes and Sex Hormones: Dissecting the Forces That Differentiate Female and Male Hearts.Circulation · 2025Review
- S-nitrosylation of cardiac myocyte proteins may underlie sex differences in cardiac disease.Frontiers in physiology · 2025Review
- Mechanism of Ershen Zhenwu Decoction in ameliorating chronic heart failure via JNK/MAPK-regulated apoptosis: insights from network pharmacology and experimental validation.Frontiers in cardiovascular medicine · 2025Article
- An In Vivo Model of Estrogen Supplementation Concerning the Expression of CaJournal of cardiovascular development and disease · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Heart failure (HF) is a significant public health problem worldwide. It has long been noted that premenopausal women, compared to postmenopausal women and men, have lower rates for developing this disease, as well as subsequent morbidity and mortality. This difference has been attributed to estrogen playing a cardioprotective role in these women, though exactly how it does so remains unclear. In this review, we examine the presence of estrogen receptors within the cardiovascular system, as well as the role they play behind the cardioprotective effect attributed to estrogen. Furthermore, we highlight the underlying mechanisms behind their alleviation of HF, as well as possible treatment approaches, such as hormone replacement therapy and exercise regimens, to manipulate these mechanisms in treating and preventing HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.